RLMD — RELMADA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1553643 ·
Last close
$3.01
Market Cap
$321.15M
52W High
$8.00
52W Low
$2.98
ADV30
1,666,920
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -13,096,423 | -13,862,188 | 205,296,615 | 5,720,325 | 11,559,554 |
| Jun 2026 | 0 | — | -15,011,027 | -12,914,185 | 219,059,177 | 11,334,370 | 12,500,854 |
| Mar 2026 | 0 | — | -19,461,754 | -19,051,956 | 235,362,794 | 9,776,400 | 16,630,217 |
| Dec 2025 | 0 | — | -20,333,112 | -19,867,760 | 94,003,471 | 3,496,540 | 7,491,458 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,992,000
Investing CF
$-187,818,172
Financing CF
$243,791,191
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-730,233,339
Inventory
—
Receivables
$10,912
ST Investments
$206,396,805
EBIT TTM
$-65,133,239
Pretax Income TTM
$-61,925,397
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,100,200 | -57,385,163 | 94,003,471 | 7,491,458 | 86,512,013 | -45,786,988 |
| Dec 2024 | 0 | -83,891,036 | -79,979,354 | 45,817,818 | 10,295,857 | 35,521,961 | -51,755,798 |
| Dec 2023 | 0 | -103,702,293 | -98,791,746 | 97,552,042 | 12,194,800 | 85,357,242 | -51,659,206 |
| Dec 2022 | 0 | -161,249,076 | -157,043,823 | 152,905,179 | 12,468,877 | 140,436,302 | -103,801,617 |
TTM Snapshot
Revenues TTM
$3,895,400
NetIncome TTM
$-61,925,397
OpCashFlow TTM
—
Assets (Latest)
$219,059,177
Forward EPS
$-0.41
Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.85 · call volume: 652 · put volume: 2Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | $318.00M | $3.96 | — |
| LRMR | Larimar Therapeutics, Inc. | $310.61M | $2.99 | — |
| LYEL | Lyell Immunopharma, Inc. | $336.08M | $13.67 | — |
| CTNM | Contineum Therapeutics, Inc. | $337.62M | $9.55 | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $305.31M | $1.63 | — |
News headlines (Yahoo Finance, 1h cache)
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
2026-11-16 07:00 · Yahoo
Relmada Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Relmada (RLMD) Q3 2026 Earnings Call Transcript
2026-11-13 05:43 · Yahoo
What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
2026-11-13 05:14 · Yahoo
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
2026-11-04 12:00 · Yahoo
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
2026-11-03 12:00 · Yahoo
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
2026-08-31 13:35 · Yahoo
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
2026-08-25 13:55 · Yahoo
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
2026-08-11 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.